Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The diabetic brain and cognition.
Riederer P, Korczyn AD, Ali SS, Bajenaru O, Choi MS, Chopp M, Dermanovic-Dobrota V, Grünblatt E, Jellinger KA, Kamal MA, Kamal W, Leszek J, Sheldrick-Michel TM, Mushtaq G, Meglic B, Natovich R, Pirtosek Z, Rakusa M, Salkovic-Petrisic M, Schmidt R, Schmitt A, Sridhar GR, Vécsei L, Wojszel ZB, Yaman H, Zhang ZG, Cukierman-Yaffe T. Riederer P, et al. Among authors: bajenaru o. J Neural Transm (Vienna). 2017 Nov;124(11):1431-1454. doi: 10.1007/s00702-017-1763-2. Epub 2017 Aug 1. J Neural Transm (Vienna). 2017. PMID: 28766040 Review.
Update on the Management of Parkinson's Disease for General Neurologists.
Pirtošek Z, Bajenaru O, Kovács N, Milanov I, Relja M, Skorvanek M. Pirtošek Z, et al. Among authors: bajenaru o. Parkinsons Dis. 2020 Mar 26;2020:9131474. doi: 10.1155/2020/9131474. eCollection 2020. Parkinsons Dis. 2020. PMID: 32300476 Free PMC article. Review.
Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?
Catalán MJ, Antonini A, Calopa M, Băjenaru O, de Fábregues O, Mínguez-Castellanos A, Odin P, García-Moreno JM, Pedersen SW, Pirtošek Z, Kulisevsky J. Catalán MJ, et al. Among authors: bajenaru o. eNeurologicalSci. 2017 Jul 2;8:44-53. doi: 10.1016/j.ensci.2017.06.004. eCollection 2017 Sep. eNeurologicalSci. 2017. PMID: 29260038 Free PMC article. Review.
Application of the '5-2-1' screening criteria in advanced Parkinson's disease: interim analysis of DUOGLOBE.
Aldred J, Anca-Herschkovitsch M, Antonini A, Bajenaru O, Bergmann L, Bourgeois P, Cubo E, Davis TL, Iansek R, Kovács N, Kukreja P, Onuk K, Pontieri FE, Robieson W, Siddiqui MS, Simu M, Standaert DG, Chaudhuri KR. Aldred J, et al. Among authors: bajenaru o. Neurodegener Dis Manag. 2020 Oct;10(5):309-323. doi: 10.2217/nmt-2020-0021. Epub 2020 Sep 2. Neurodegener Dis Manag. 2020. PMID: 32873195 Free article. Clinical Trial.
How does fingolimod (gilenya(®)) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?
Fazekas F, Bajenaru O, Berger T, Fabjan TH, Ledinek AH, Jakab G, Komoly S, Kobys T, Kraus J, Kurča E, Kyriakides T, Lisý L, Milanov I, Nehrych T, Moskovko S, Panayiotou P, Jazbec SŠ, Sokolova L, Taláb R, Traykov L, Turčáni P, Vass K, Vella N, Voloshyná N, Havrdová E. Fazekas F, et al. Among authors: bajenaru o. Front Neurol. 2013 May 1;4:10. doi: 10.3389/fneur.2013.00010. eCollection 2013. Front Neurol. 2013. PMID: 23641231 Free PMC article.
Acute response to cholinergic challenge predicts long-term response to galantamine treatment in patients with Alzheimer's disease.
Baakman AC, Gavan C, van Doeselaar L, de Kam M, Broekhuizen K, Bajenaru O, Camps L, Swart EL, Kalisvaart K, Schoonenboom N, Lemstra E, Scheltens P, Cohen A, van Gerven J, Groeneveld GJ. Baakman AC, et al. Among authors: bajenaru o. Br J Clin Pharmacol. 2022 Jun;88(6):2814-2829. doi: 10.1111/bcp.15206. Epub 2022 Jan 26. Br J Clin Pharmacol. 2022. PMID: 34964149 Free PMC article. Clinical Trial.
Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome.
Comi G, Martinelli V, Rodegher M, Moiola L, Leocani L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Preziosa P, Ravnborg M, Rieckmann P, Rocca MA, Wynn D, Young C, Filippi M. Comi G, et al. Among authors: bajenaru o. Mult Scler. 2013 Jul;19(8):1074-83. doi: 10.1177/1352458512469695. Epub 2012 Dec 12. Mult Scler. 2013. PMID: 23234810 Free article. Clinical Trial.
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.
Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, Filippi M; PreCISe study group. Comi G, et al. Among authors: bajenaru o. Lancet. 2009 Oct 31;374(9700):1503-11. doi: 10.1016/S0140-6736(09)61259-9. Epub 2009 Oct 6. Lancet. 2009. PMID: 19815268 Clinical Trial.
A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.
Ziemssen T, Bajenaru OA, Carrá A, de Klippel N, de Sá JC, Edland A, Frederiksen JL, Heinzlef O, Karageorgiou KE, Lander Delgado RH, Landtblom AM, Macías Islas MA, Tubridy N, Gilgun-Sherki Y. Ziemssen T, et al. Among authors: bajenaru oa. J Neurol. 2014 Nov;261(11):2101-11. doi: 10.1007/s00415-014-7446-0. Epub 2014 Aug 14. J Neurol. 2014. PMID: 25119836 Free PMC article.
101 results